Atnaujinkite slapukų nuostatas

Transparency, Power, and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game? [Kietas viršelis]

Edited by , Edited by , Edited by
  • Formatas: Hardback, 277 pages, aukštis x plotis x storis: 229x150x25 mm, weight: 540 g, 1 figure
  • Išleidimo metai: 22-Jun-2021
  • Leidėjas: University of Toronto Press
  • ISBN-10: 1487529031
  • ISBN-13: 9781487529031
  • Formatas: Hardback, 277 pages, aukštis x plotis x storis: 229x150x25 mm, weight: 540 g, 1 figure
  • Išleidimo metai: 22-Jun-2021
  • Leidėjas: University of Toronto Press
  • ISBN-10: 1487529031
  • ISBN-13: 9781487529031

Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry to account through greater transparency.



There is plenty of controversy surrounding pharmaceuticals, but it cannot be denied that the pharmaceutical industry is both socially beneficial and profitable. Regulators are expected to ensure that the economic success of the industry does not come at the expense of public safety, yet they have also assumed a cooperative role by providing advice on regulation and by targeting unmet medical needs. Concerns over regulatory standards, conflicts of interest, and the manipulation of information on drug safety and effectiveness have led to public mistrust and a greater need for transparency between the pharmaceutical industry and government regulators.

Transparency, Power, and Influence in the Pharmaceutical Industry evaluates the progress made in holding the pharmaceutical industry responsible for creating transparency in the industry, from development to market. The contributors to this volume examine the various mechanisms introduced to make the regulatory process more informative and situate these efforts within the larger project of enhancing the safety of drugs, vaccines, and other products.

1 Introduction
3(10)
Katherine Fierlbeck
Janice Graham
Matthew Herder
2 Transparency, Pharmaceuticals, And The Problem Of Policy Change
13(50)
Katherine Fierlbeck
3 Data Transparency And Pharmaceutical Regulation In Europe: Road To Damascus, Or Room Without A View?
63(32)
Courtney Davis
Shai Mulinari
Tom Jefferson
4 The Fda And Health Canada: Similar Origins, Yet Divergent Paths And Approaches To Transparency
95(19)
Margaret E. Mccarthy
Joseph S. Ross
5 Clinical Trial Data Transparency In Canada: Mapping The Progress From Laggard To Leader
114(15)
Marc-Andre Gagnon
Matthew Herder
Janice Graham
Katherine Fierlbeck
Anna Danyliuk
6 The Limits Of Transparency And The Role Of Essential Medicines
129(10)
Nav Persaud
7 Speak No Secrets: (Non) Transparency In Health Canada's Communications About Pharmaceutical Regulation
139(20)
Joel Lexchin
8 The Political Economy Of Influence: Ghost-Management In The Pharmaceutical Sector
159(25)
Marc-Andre Gagnon
9 Data Transparency And Rare Disease: Privacy Versus Public Interest?
184(35)
Kanksha Mahadevia Ghimire
Trudo Lemmens
10 The European Registration Of The Pandemic Influenza Vaccine Pandemrix: A Case Study Of The Consequences Of Poor Clinical Data Transparency
219(24)
Tom Jefferson
11 The Road Forward: How Researchers Can Sustain An Ethical And Transparent Health System
243(18)
Rita Banzi
12 Conclusion
261(16)
Katherine Fierlbeck
Janice Graham
Matthew Herder
Contributors 277(4)
Index 281
Katherine Fierlbeck is the McCulloch Professor of Political Science at Dalhousie University, with a cross-appointment as professor of Community Health and Epidemiology.

Janice Graham is a professor of Paediatrics (infectious diseases) and Medical Anthropology, and the University Research Professor at Dalhousie University.

Matthew Herder is the director of the Health Law Institute and an associate professor of Medicine and Law at Dalhousie University.